Search results
Antonio Colombo
Research Area(s) / Expertise:
Job title: Director, Cardiac Cath Lab and Interventional Cardiology Unit
Author
Author(s):
Pierluigi Costanzo
,
Paul Bamborough
,
Mark Peterson
,
et al
Added:
1 year ago
Author(s):
Neil Ruparelia
Added:
3 years ago
Transcatheter aortic valve implantation (TAVI) is now the accepted treatment option of choice for patients presenting with severe symptomatic aortic stenosis who are deemed to be inoperable or of high surgical risk.1,2 Short- and intermediate-term outcomes have been promising3–5 and with increasing institutional and operator experience combined with technological advancements there has been…
View more
Author(s):
Maurizio Taramasso
,
Christelle Calen
,
Andrea Guidotti
,
et al
Added:
3 years ago
The leading aetiology of tricuspid regurgitation (TR) in developed countries is functional, secondary to left side heart disease and pulmonary hypertension.1 Currently, moderate-to-severe TR affects approximately 1.6 million patients in the United States, of whom only 8,000 undergo tricuspid surgery annually;2 this results in an extremely large number of untreated patients with significant TR, a…
View more
Eugene Braunwald
Research Area(s) / Expertise:
Job title: Distinguished Hersey Professor of Medicine, MACC
Author
Broadening TEER Options for Your Patients
Video Series
Author(s):
Hellmuth Weich
Added:
3 years ago
There has been a recent explosion in the field of transcatheter aortic and pulmonary valve replacements, but the atrio-ventricular valves have lagged behind for various reasons with the tricuspid valve undoubtedly the least treated valve of the four. Despite the fact that tricuspid regurgitation (TR) can result in significant symptoms, patients are rarely referred for isolated surgical tricuspid…
View more
Author(s):
Azfar Zaman
,
Bernard Prendergast
,
David Hildick-Smith
,
et al
Added:
1 year ago
Author(s):
Pascal Thériault-Lauzier
,
Marco Spaziano
,
Beatriz Vaquerizo
,
et al
Added:
3 years ago
Valvular Disease
Aortic valve
Severe symptomatic aortic stenosis (AS) bears a dismal prognosis. The mean survival is 2.0 to 4.7 years after the onset of angina, 0.8 to 3.8 years after the onset of syncope and 0.5 to 2.8 years after the onset of congestive heart failure.1 Surgical aortic valve replacement (SAVR) is the mainstay of treatment for these patients.2 In the last decade transcatheter…
View more
Anticoagulation after TAVI
Author(s):
Antonio Greco
,
Davide Capodanno
Added:
3 years ago
Article